Compare Raymond James Financial, Inc. (RJF) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Twist Bioscience Corp — how do they compare? Raymond James Financial, Inc. trades at $175.81 (market cap $33.75B), while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Raymond James Financial, Inc. is far larger — about 4.1× Twist Bioscience Corp's market cap, and Raymond James Financial, Inc. pays a 1.23% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| RJF | TWST | |
|---|---|---|
Market Cap | $33.75B | $8.26B |
Sector | Financials | Health |
52-Week High | $181.18 | $153.10 |
52-Week Low | $140.89 | $24.16 |
Dividend Yield | 1.23% | — |
Enterprise Value | — | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $176.55, down 0.98% on the day, with a mixed technical picture showing bearish overall signals but bullish moving averages. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $3.14 beating estimates of $2.93, and revenue growth from $10.9B in 2022 to $13.84B in 2025. Recent developments include dividend declarations and PGA TOUR sponsorship announcements.
RJF presents a balanced investment case with 44% analyst buy ratings and a $184.11 consensus price target offering 4.3% upside. Strengths include consistent earnings growth and wealth management expansion, while risks involve rising expenses and capital market volatility. The stock trades at reasonable valuations with P/E of 15.39 and P/S of 2.36, supported by 15.37% net margins.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
